GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the Endocrine Society’s annual meeting.
Weight loss from lifestyle changes or bariatric surgery is known to boost testosterone levels, but the impact of anti-obesity medications has not been widely investigated, study leader Dr. Shellsea Portillo Canales of SSM Health St. Louis University Hospital in Missouri said in a statement.
Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other ‘disruptive’ innovations. Subscribe to our newsletter.
Portillo Canales and colleagues tracked 110 men with obesity – many also with type 2 diabetes – who were being treated with semaglutide, dulaglutide or tirzepatide, the active ingredients in Novo Nordisk’s Wegovy and Ozempic or Eli Lilly’s Trulicity, Mounjaro, and Zepbound.
The average age was 54. None of the men were receiving other testosterone-boosting medications.
During 18 months of treatment, the proportion of men with testosterone levels in the normal range rose from 53% to 77%.
…
While the study cannot prove GLP-1 drugs caused low testosterone levels to normalize, it does show a direct correlation, Portillo Canales noted.
This is an excerpt. Read the original post here